Continuous Renal Replacement Therapy for Acute Kidney Injury Using Phosphate Containing Fluid is Associated With Greater Biochemical Derangement than Conventional Fluid
Journal Title: Nephrology – Open Journal - Year 2016, Vol 2, Issue 1
Abstract
Background: Continuous Renal Replacement Therapy (CRRT) is the preferred means of renal replacement therapy (RRT) in many intensive care units. Most units use only one type of RRT fluid or identify a standard ‘default’ fluid. Little data is available comparing the effects of using different RRT fluids. We aimed to identify the biochemical consequences of receiving CRRT with potassium and phosphate free fluid, Hemosol-B0, or potassium and phosphate containing fluid, Phoxilium, as a default RRT fluid. Methods: Retrospective observational study in a mixed Level III Intensive Care Unit (ICU). A period of two-six months study were compared during which either Hemosol-B0 or Phoxilium were used as the unit’s default fluid. Daily biochemistry results and K+ and PO4 3- supplementation were recorded in all patients over eighteen years requiring CRRT during the study period; data was collected on 35 patients in the Hemosol-B0 group and 31 patients in the Phoxilium group. Our primary outcome was the proportion of CRRT treatment during which [PO4 3-], [Ca2+]pl and [HCO3 - ]pl were in the normal range, and secondary outcome the need for non-RRT fluid K+ and PO4 3- supplementation. Results: Phoxilium was associated with a greater proportion of the CRRT delivery time spent with [PO4 3-] above the normal range. Furthermore, Phoxilium was associated with more time spent with ionised [Ca2+]pl and [HCO3 - ]pl below the normal range. Phoxilium significantly decreased the requirement for phosphate but not potassium supplementation. Conclusions: Patients receiving Phoxilium should be monitored to avoid hyperphosphataemia, hypocalcaemia and metabolic acidosis. Phoxilium use does not abrogate the need to handle concentrated potassium solutions.
Authors and Affiliations
Victoria A. Bennett
Keywords
Related Articles
- EP ID EP558260
- DOI 10.17140/NPOJ-2-114
- Views 126
- Downloads 0
Nephrology should Trail Blaze the End of Chronic Disease
If history can serve as a guide quite some time can lapse between the inception of a concept and its proof. For instance, Einstein had described the special theory of relativity in 1905, but he published the general theo...
The Unfolded Protein Response: A Novel Insight into Chronic Kidney Disease (CKD)
Chronic kidney disease (CKD) is a clinical syndrome, characterized by a progressive decline of renal function. CKD is associated with a wide range of metabolic abnormalities including hypertension, anemia, acidosis, and...
Androgen and Androgen Receptor in Kidney Cancer
Kidney cancer is one of the top ten most common cancers in men and women. There are four types of kidney cancer, including Renal Cell Carcinoma (RCC), Transitional cell carcinoma, renal sarcoma, and Wilm’s tumor. The mos...
Kidney Ischemia and Reperfusion Injury – Field of Glory or Warterloo for Erythropoietin?
When asking clinicians about their knowledge about Erythropoietin (EPO) most of them would say that it increases Red Blood Cell (RBC) count and can therefore be used to treat anemia, is produced in the kidneys and can be...
The Epidermal Growth Factor Receptor: A Potential Therapeutic Target in ChronicKidney Disease
Chronic kidney disease (CKD) is a clinical syndrome characterized by a gradual loss of kidney function that persists for >3 months with health implications and affects nearly 500 million people worldwide. Diabetes and hy...